Pipeline
Different biology.Different possibilities.
OP01 — NextGen leads the pipeline in Major Depressive Disorder. Behind it, Object Pharma is building a platform of differentiated neurotoxin opportunities.
One lead program.
A platform behind it.
Lead
OP01 — NextGen
Major Depressive Disorder
Mental & brain health
Preclinical
Platform
Selected neurotoxin development opportunities. Program details pending corporate approval.
OP02
Pending approval
Pending approval
Pending approval
OP03
Pending approval
Pending approval
Pending approval
Broader applications
Potential therapeutic and aesthetic applications arising from differentiated neurotoxin biology. Exploratory — not active clinical programs.
Future possibilities arising from Object Pharma's neurotoxin science and the ObNowa European platform — communicated as scientific optionality, not as disclosed development programs.
Program nomenclature, molecules, indications, development stages, territories and Object / ObNowa relationships beyond OP01 are under corporate review. This page will be updated once program details are approved for publication.
